These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 19220547

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
    Phillips JA, Bell SC.
    Intern Med J; 2001; 31(1):23-6. PubMed ID: 11478352
    [Abstract] [Full Text] [Related]

  • 4. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA.
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [Abstract] [Full Text] [Related]

  • 5. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.
    Kim MJ, Bertino JS, Erb TA, Jenkins PL, Nafziger AN.
    J Clin Pharmacol; 2004 Jul; 44(7):696-707. PubMed ID: 15199074
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J.
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.
    Graham AC, Mercier RC, Achusim LE, Pai MP.
    Ann Pharmacother; 2004 Jun; 38(6):936-41. PubMed ID: 15084688
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
    Madsen V, Lind A, Rasmussen M, Coulthard K.
    J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
    [Abstract] [Full Text] [Related]

  • 19. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M, Kotaska K, Kukacka J, Vavrova V, Kuzelova M, Ticha J, Prusa R.
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.